drugset / Trial / NCT00493129
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
NaSingle-groupOpen-labelTreatment
Summary
Primary Objective: 1\. To assess the response rate of ONTAK in Systemic Mastocytosis (SM) patients. Secondary Objectives: 1. To assess the safety of ONTAK in SM patients. 2. To evaluate the time to progression and duration of response following treatment with ONTAK.
Timeline
- Start
- 2004-07
- Primary completion
- 2007-08
- Completion
- 2007-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | denileukin diftitox | Protein / enzyme biologic | 9 ug/kg | Intravenous |